ArticleBMC cancer2026
Integrated analysis of miR-15a-5p, miR-20a-5p, and miR-33b-3p identifies EGR2-associated biomarkers in multiple myeloma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Promoter Methylation of HOXA5 and NDRG2 in Multiple Myeloma Patients with Renal Impairment.Biochemical genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecently miR-15a-5p, miR-20a-5p and miR-33b-3p were found to be abnormally expressed in multiple myeloma (MM) patients. However, the significance of these microRNAs in MM pathogenesis remains poorly understood. Therefore the aim of the current study was to make an integrated bioinformatics analysis of miR-15a-5p, miR-20a-5p and miR-33b-3p to identify the biological processes in MM pathogenesis.
methodsThe Steven K. Thompson equation and a-priori power analysis was conducted to determine the minimum sample size required. Forty patients with newly diagnosed MM and staged by the International Staging System (ISS) and 20 healthy bone marrow donors were included in our study. The baseline bone marrow miR-15a-5p, miR-20a-5p and miR-33b-3p expression levels were evaluated by RTqPCR technique. Moreover, EGR2 expression level was evaluated by using immunohistochemistry. A bioinformatics analysis for miR-15a-5p, miR-20a-5p, miR-33b-3p and EGR2 was done by using miRNet and miRDB (for target genes prediction), GO analysis and KEGG analysis (for biological processes identification) and STRING database (for PPI network).
resultsThe target genes of miR-15a-5p, miR-20a-5p and miR-33b-3p were retrieved then GO analysis was done which showed that the pathway with many shared target genes was MAPK signaling pathway that involved in the cell cycle control. The baseline bone marrow miR-15a-5p, miR-20a-5p& miR-33b-3p expression levels were significantly decreased (0.29 ± 0.04, p < 0.001;0.42 ± 0.06, p < 0.001;0.51 ± 0.07, p = 0.02 fold-change relative to controls) in MM patients when compared to controls (1.04 ± 0.11,1.02 ± 0.07&1.05 ± 0.11;respectively) while EGR2 protein was significantly increased in MM patients when compared to controls. Results obtained from ROC curve revealed that miR-15a-5p + miR-20a-5p + miR-33b-3p panel (AUC = 0.98, 100%sensitivity, 85%specificity, p < 0.001) and EGR2 protein expression (AUC = 0.986, 97.5%sensitivity, 90%specificity, p < 0.001) were the best ones as diagnostic biomarkers could differentiate MM disease. By using Kaplan − Meier survival test, the mean (95%CI) for OS was 24.08 (21.58–29.88) months throughout the 32-month follow-up period for MM patients, our results indicated that patients with lower expression levels of miR-15a-5p, miR-20a-5p&miR-33b-3p and higher expression level of EGR2 protein had poorer prognosis and possessing a shorter OS. The logistic regression analysis indicates that miR-15a-5p, miR-20a-5p, and miR-33b-3p are risk factors for the development of MM (OR = 9.36,2.56,4.76; 95% CI 4.02–21.28,1.28–5.32,2.43–9.16; p < 0.001, p = 0.016, p < 0.001;respectively).
conclusionFinally miR-15a-5p, miR-20a-5p, and miR-33b-3p may have roles in MM pathogenesis through cell cycle control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.